Yes, there is a meaningful difference. Polycythemia is a broad term for any condition involving too many red blood cells in your body. Polycythemia vera is one specific type of polycythemia, a blood cancer caused by a genetic mutation in the bone marrow. The confusion is understandable because doctors and patients often use “polycythemia” as shorthand for polycythemia vera, but the two are not the same thing.
Polycythemia: The Umbrella Term
Polycythemia simply means your red blood cell count is higher than normal. That excess can be real (your body is genuinely making too many red blood cells) or apparent (your blood plasma volume has dropped, making it look like you have more red cells than you actually do). The apparent version, sometimes called spurious polycythemia, can happen with severe dehydration from vomiting or diarrhea, heavy alcohol use, smoking, or diuretic medications. Once the underlying cause is corrected, red blood cell levels return to normal.
When the increase in red blood cells is real, doctors split it into two categories based on what’s driving the overproduction:
- Primary polycythemia: The problem originates in the bone marrow itself. Polycythemia vera falls here.
- Secondary polycythemia: Something outside the bone marrow is signaling it to make more red blood cells, usually low oxygen levels in the body.
Common Causes of Secondary Polycythemia
Secondary polycythemia is far more common than polycythemia vera and is driven by conditions that reduce oxygen delivery to your tissues. When your body senses low oxygen, it ramps up production of a hormone called erythropoietin (EPO), which tells the bone marrow to churn out more red blood cells. This is actually your body doing its job correctly in response to a problem elsewhere.
The most frequent triggers include chronic lung diseases like COPD, obstructive sleep apnea, obesity hypoventilation syndrome, smoking (carbon monoxide in cigarette smoke reduces oxygen-carrying capacity), cyanotic heart disease, and living at high altitude. Certain kidney conditions that create localized oxygen deprivation can also drive EPO production. In rarer cases, anabolic steroid use or direct EPO injections cause the same effect.
The key distinction: in secondary polycythemia, the bone marrow is healthy. It’s just responding to an external signal. Treat the underlying cause, whether that’s managing sleep apnea or quitting smoking, and red blood cell counts typically improve.
What Makes Polycythemia Vera Different
Polycythemia vera is a myeloproliferative disorder, meaning the bone marrow itself is malfunctioning. Rather than responding to normal signals, marrow cells multiply on their own, overproducing red blood cells and often white blood cells and platelets as well. This is what separates it from every other form of polycythemia: the problem is baked into the marrow’s DNA.
The condition affects an estimated 44 to 57 per 100,000 people in the United States, with men diagnosed more frequently than women. It is an acquired mutation, not something you’re born with or can catch from someone else.
Bone marrow in polycythemia vera looks distinctly abnormal under a microscope. It’s hypercellular, packed with 80 to 90 percent cell density, and shows a pattern called panmyelosis, meaning all three blood cell lines (red cells, white cells, and platelets) are growing excessively. In secondary polycythemia, the marrow may be busy but structurally normal.
The Role of the JAK2 Mutation
Nearly all patients with polycythemia vera carry a specific genetic mutation known as JAK2 V617F. In one study from the American Society of Hematology, 100% of confirmed polycythemia vera patients tested positive for this mutation, while none of the patients with secondary polycythemia carried it. A larger Egyptian study found the mutation in 80% of polycythemia vera cases. Either way, this mutation is essentially a fingerprint for the disease.
The JAK2 mutation causes a signaling protein in bone marrow cells to stay permanently switched on, telling the cells to keep dividing regardless of whether the body needs more blood cells. This is why EPO levels in polycythemia vera are typically low or suppressed: the marrow no longer needs the hormone’s instruction. In one study, over half of polycythemia vera patients had EPO levels below normal (average 3.4 mIU/mL), while secondary polycythemia patients averaged 23.7 mIU/mL, well above the normal range of 2.6 to 18.5. Checking EPO levels is one of the first steps in figuring out which type of polycythemia you have.
How Polycythemia Vera Is Diagnosed
Current diagnostic guidelines require hemoglobin above 16.5 g/dL in men or above 16.0 g/dL in women, or hematocrit above 49% in men or 48% in women. Meeting those thresholds alone doesn’t confirm polycythemia vera; it simply flags that something is going on. From there, JAK2 mutation testing and EPO levels help narrow down the cause. A bone marrow biopsy showing hypercellularity and panmyelosis can confirm the diagnosis, though updated criteria allow skipping the biopsy in JAK2-positive patients whose hemoglobin and hematocrit values are especially high (above 18.5 g/dL or 55.5% in men, above 16.5 g/dL or 49.5% in women).
Why the Distinction Matters for Your Health
All forms of polycythemia raise your risk of blood clots because thicker blood flows less smoothly through your vessels. But polycythemia vera carries additional dangers that secondary polycythemia does not. Because it is a bone marrow cancer, it can progress over time. Roughly 5% of patients develop bone marrow scarring (myelofibrosis) within 10 years of diagnosis, about 9% by 15 years, and around a quarter by 20 years. There is also a small but real risk of transformation into acute leukemia.
Secondary polycythemia doesn’t carry these progression risks. Once the underlying cause is addressed, the condition itself resolves or stabilizes.
How Treatment Differs
For secondary polycythemia, treatment targets the root cause. Managing COPD, treating sleep apnea with a CPAP machine, quitting smoking, or moving from high altitude can all bring red blood cell counts back toward normal without needing to treat the blood itself.
Polycythemia vera requires ongoing management because the bone marrow defect doesn’t go away. The primary goal is keeping hematocrit below 45% to reduce clot risk. This is most commonly achieved through periodic blood removal (phlebotomy), where a unit of blood is drawn to bring levels down, similar to donating blood. Many patients need this every few weeks initially, then less frequently as levels stabilize. For patients at higher risk of clots, medications that suppress bone marrow activity are added to keep blood cell production in check. Low-dose aspirin is also standard for most patients to reduce clotting tendency.
The lifelong nature of polycythemia vera management is one of the starkest practical differences from secondary polycythemia. You’ll need regular blood counts and hematologist visits indefinitely, with treatment adjustments as the disease evolves over years or decades.